Aravive (ARAV) Stock Price, News & Analysis

Company Overview

Aravive, Inc., a clinical-stage biopharmaceutical company, develops transformative treatments for life-threatening diseases, including cancer and fibrosis in the United States. Its lead product candidate is batiraxcept, an ultrahigh-affinity, decoy protein that targets the GAS6-AXL signaling pathway, which is in Phase III clinical trial for the treatment of platinum- resistant recurrent ovarian cancer; and in Phase Ib/II clinical trial for the treatment of clear cell renal cell carcinoma and pancreatic adenocarcinoma. The company also develops AVB-S6, a soluble Fc-fusion protein to block the activation of the GAS6-AXL signaling pathway. It has a license and collaboration agreement with WuXi Biologics (Hong Kong) Limited to identify and develop novel high-affinity bispecific antibodies targeting cancer and fibrosis; and license agreement with 3D Medicines Inc. to develop products that contain batiraxcept as the sole drug substance for the treatment of human oncological diseases in mainland China, Taiwan, Hong Kong, and Macau. The company was formerly known as Versartis, Inc. and changed its name to Aravive, Inc. in October 2018. Aravive, Inc. was incorporated in 2008 and is headquartered in Houston, Texas.

Key Stats

• Today's Range: $0.04 to $0.04
• 50-Day Range: $0.04 to $0.04
• 52-Week Range: $0.04 to $2.46
• Volume: N/A
• Average Volume: N/A
• Market Capitalization: $2.95 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Aravive Stock Analysis - MarketRank™

Aravive scored higher than 14% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Aravive.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Aravive is -0.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Aravive is -0.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Aravive has a P/B Ratio of 0.22. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for ARAV.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Aravive does not currently pay a dividend.

Dividend Growth

Aravive does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.6 / 5
• Environmental Score: -0.77

Short Interest

There is no current short interest data available for ARAV.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for Aravive this week, compared to 0 articles on an average week.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Aravive insiders have not sold or bought any company stock.

Percentage Held by Insiders

60.40% of the stock of Aravive is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 35.80% of the stock of Aravive is held by institutions.

ARAV Stock Analysis - Frequently Asked Questions

How have ARAV shares performed this year?

Aravive's stock was trading at $0.1237 at the start of the year. Since then, ARAV stock has decreased by 67.6% and is now trading at $0.0401.
View the best growth stocks for 2024 here.

How were Aravive's earnings last quarter?

Aravive, Inc. (NASDAQ:ARAV) released its quarterly earnings results on Wednesday, October, 27th. The company reported ($0.53) EPS for the quarter, missing analysts' consensus estimates of ($0.46) by $0.07. The company earned $2.41 million during the quarter, compared to the consensus estimate of $2.36 million.

How do I buy shares of Aravive?

Shares of ARAV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Aravive own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Aravive investors own include Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), SCYNEXIS (SCYX), VBI Vaccines (VBIV), Applied Genetic Technologies (AGTC), Flexion Therapeutics (FLXN) and Inovio Pharmaceuticals (INO).

Company Calendar

• Last Earnings: 10/27/2021
• Today: 10/05/2024
• Next Earnings (Estimated): 11/14/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ARAV
• CUSIP: N/A
• CIK: 1513818
• Web: www.aravive.com
• Phone: (936) 355-1910
• Fax: N/A
• Employees: 20
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $9.14 million
• Price / Sales: 0.32
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.18 per share
• Price / Book: 0.22

Miscellaneous

• Outstanding Shares: 73,560,000
• Free Float: 29,131,000
• Market Cap: $2.95 million
• Optionable: No Data
• Beta: N/A